Establishes "Cindi's Law" requiring certain diagnostic tests for uterine cancer

SB 842, titled "Cindi's Law," requires medical facilities to perform a p53 test on all abnormal endometrial tissue samples collected for diagnosis. This applies specifically to samples obtained through endometrial sampling procedures (tissue collection from the uterine lining). The p53 test detects protein abnormalities to help assess cancer invasiveness, severity, and prognosis, supplementing existing diagnostic tests. The law mandates this addition to standard testing protocols for uterine cancer diagnosis and treatment planning. It directly affects healthcare providers conducting endometrial biopsies in Missouri.